ASH 2020
Findings presented at the ASH 2020 Annual Meeting & Exposition found that almost half of patients with multiple ...
This study enrolled 200 patients being treated for MM with IMiDs at the Dana Farber Cancer Center in Massachusetts.
During the recently concluded American Society for Hematology (ASH) meeting, researchers reported the most recent ...
Insurance status was found to be significantly associated with survival for patients with multiple myeloma (MM), ...
The honor was bestowed upon him for his work in promoting minority and women hematologists during his career.
Multiple myeloma (MM) is a rare and heterogeneous blood cancer of the plasma cells. Although therapies have been ...
Results from the PRIME study, presented at the ASH Annual Meeting & Exposition, found that P-BCMA-101, an autologous ...
Data presented at the ASH 2020 Annual Meeting (abstract #412) showed that subcutaneous daratumumab plus pomalidomide and ...
The novel chimeric antigen receptor (CAR) T cell therapy, CT053, achieved a 100% overall response rate (ORR) for the ...
Iberdomide, an oral potent novel cereblon E3 ligase modulator (CELMoD), in combination with other agents demonstrated an ...
A study presented at the ASH Annual Meeting & Exposition found that among six landmark multiple myeloma (MM) ...
cilta-cel is a structurally distinct second-generation chimeric antigen receptor therapy with two BCMA-binding domains.
Ajai Chari, MD, PhD, of Mount Sinai Medical Center discusses findings from a phase I study of the novel agent, talquetamab.
Enrollment in the phase I dose escalation portion is ongoing, and the phase II portion of the study is recruiting.
Advertisement
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.